Flynn James E, 10% Owner, subtracted 699,475 shares of Aclaris Therapeutics, Inc. (ACRS) from its portfolio at the rate of $2.69 per share valuing $1,882,077 on Jun 27. The insider left behind 964,101 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Aclaris Therapeutics, Inc. (ACRS) was $0.79. Currently, the 1st Resistance Point for this stock is $0.84, with a 2nd Resistance Point sitting at $0.90. Meanwhile, this company’s stock has a 1st Support Level at $0.76 and a 2nd Support Level at $0.73. Aclaris Therapeutics, Inc. (ACRS) stock has lost -$0.23, or -22.92%, in the past five days. In the last full month, these shares have lost -$1.39, or -63.94%. In the past three months, this stock’s price has fallen by -$4.94, or -86.28%. This year-to-date, Aclaris Therapeutics, Inc. (ACRS) shares have lost -$6.60, or -89.36%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Aclaris Therapeutics, Inc. (ACRS) stock, 100% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 100% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100 – 200 Day MACD Oscillator % of long-term indicators suggest that this stock is a “.”
With 41,368 K shares outstanding, this company currently has a market capitalization of $34,240K. Aclaris Therapeutics, Inc. (ACRS) generates $10,090 K in annual sales, amounting to annual net income of -$132,740 K. This stock has generated a 1-Year Total Return of -95.17%, a 3-Year Total Return of -96.10%, and a 5-year Total Return of 0.00%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Jun-19, Aclaris Therapeutics, Inc. (ACRS) reported earnings of -$0.76 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.76 per share, representing a 0 difference and -0.33% surprise. In the previous quarter ending in Mar-19, the reported earnings of -$0.91 represented a -0.11 difference from the consensus estimate calling for -$0.80 per share, which was a -13.40% surprise.
For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is -$0.69 per share. This estimate came from a total of 3 Wall Street Analysts. Of those market experts, the high estimate was -$0.65 and the low estimate was -$0.73. In the year-ago quarter, Aclaris Therapeutics, Inc. (ACRS) generated per-share earnings of -$1.06. If the analysts are correct about the current quarter’s earnings, the growth will be +34.91% .
Turning our focus now to insider trading activity, there have been 1 purchases (6,000 shares in total) and 11 sale (1,157,088 shares in total) in the last 3 months. In the last 6 months, there have been 1 insider buys amounting to 6,000 shares and 15 insider sales amounting to 1,771,798 shares. In the past full year, 20 insider purchases were made (involving 426,572 shares) and 31 insider sell-offs equivalent to 1,782,428 shares.
Moving onto liquidity, Aclaris Therapeutics, Inc. (ACRS) has a Current Ratio of 6.56, a Quick Ratio of 6.54 and a Cash Ratio of 6.14. Looking at this company’s capital structure, its Total Debt to Total Equity is 14.18, its Total Debt to Total Capital is 12.42, and its Total Debt to Total Assets is now 11.07. Looking even further ahead into the future, its Long-Term Debt to Equity is 13.91 and its Long-Term Debt to Total Capital is 12.18.